Drug Trial Radar · NCT04817332
STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19
Last checked: Nov 19, 2026Latest source record: Aug 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
406
Actual
Start
Jun 5, 2020
Primary completion
Feb 28, 2021
Study completion Feb 28, 2021
Sponsor
- Lead sponsor
- University of DundeeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- NHS Tayside; Insmed Incorporated
- First posted
- Mar 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
COVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2) and causes substantial morbidity and mortality. There is currently no vaccine to prevent infection with SARS-CoV-2 and no therapeutic agent to treat COVID-19. This clinical trial is designed to evaluate the potential of Brensocatib (INS1007) as a novel host directed therapy for the treatment of adult patients hospitalized with COVID-19. The investigators hypothesise that Brensocatib, by blocking damaging neutrophil proteases, will reduce the incidence of acute lung injury and acute respiratory distress syndrome (ARDS) in patients with COVID-19, thereby resulting in improved clinical outcomes at day 15 and day 29, fewer days dependent on oxygen or mechanical ventilation, and shorter length of hospital stay. High rates of patients requiring mechanical ventilation and overwhelming intensive care unit capacity has been the major issue contributing to excess deaths in Italy and Spain during the pandemic and is likely to be a major issue in other countries such as the United Kingdom in the coming weeks. Treatments that could prevent the requirement for mechanical ventilation or shorten the duration of ICU stay by reducing the severity of ARDS are therefore the number 1 target for COVID19 therapy. The investigators recently conducted a large phase 2 study of Brensocatib in patients with bronchiectasis designed to test if treatment with Brensocatib could reduce infective exacerbations and reduce neutrophil elastase activity in the lung in bronchiectasis patients. The study met its primary endpoint of time to first exacerbation and key secondary endpoint of the frequency of exacerbations as well as showing marked reductions in neutrophil elastase concentrations in sputum. Participants will be randomised to receive Brensocatib or placebo 25mg orally once daily for 28 days.
Conditions
- Covid19
Interventions
BrensocatibDrug
Selective, competitive, and reversible inhibitor of DPP1
PlaceboDrug
Matched placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Comparison of Participant Clinical Status Between Treatment ArmsTime frame: Up to 29 days
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
NHS Grampian
Aberdeen, United Kingdom
Royal United Hospitals Bath NHS Foundation Trust
Bath, United Kingdom
University Hospitals Birmingham NHS Foundation Trust
Birmingham, United Kingdom
Cardiff & Vale University Health Board
Cardiff, United Kingdom
NHS Tayside
Dundee, United Kingdom
NHS Fife
Dunfermline, United Kingdom
Frimley Health NHS Foundation Trust
Frimley, United Kingdom
Princess Alexandra Hospital NHS Trust
Harlow, United Kingdom
NHS Highland
Inverness, United Kingdom
NHS Forth Valley
Larbert, United Kingdom
University Hospitals of Leicester NHS Trust
Leicester, United Kingdom
Liverpool University Hospitals NHS Foundation Trust
Liverpool, United Kingdom
Portsmouth Hospitals NHS Trust
Portsmouth, United Kingdom
Sheffield Teaching Hospitals NHS Foundation Trust
Sheffield, United Kingdom
University Hospitals North Midlands NHS Trust
Stoke-on-Trent, United Kingdom
NHS Lanarkshire
Wishaw, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.